Aclaris Therapeutics Stock Price, News & Analysis (NASDAQ:ACRS)

$20.19 +0.18 (+0.90 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$20.19
Today's Range$19.86 - $20.38
52-Week Range$18.46 - $33.25
Volume119,601 shs
Average Volume355,220 shs
Market Capitalization$622.55 million
P/E Ratio-9.35
Dividend YieldN/A
BetaN/A

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics logoAclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ACRS
CUSIPN/A
Phone+1-484-3215554

Debt

Debt-to-Equity RatioN/A
Current Ratio23.43%
Quick Ratio23.44%

Price-To-Earnings

Trailing P/E Ratio-9.34722222222222
Forward P/E Ratio-7.80
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.67 per share
Price / Book3.03

Profitability

Trailing EPS($2.16)
Net Income$-48,070,000.00
Net MarginsN/A
Return on Equity-30.76%
Return on Assets-29.25%

Miscellaneous

Employees31
Outstanding Shares30,830,000

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) released its earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.23. The biotechnology company earned $0.68 million during the quarter, compared to analyst estimates of $2 million. View Aclaris Therapeutics' Earnings History.

When will Aclaris Therapeutics make its next earnings announcement?

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Aclaris Therapeutics.

Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2018?

4 brokers have issued twelve-month target prices for Aclaris Therapeutics' stock. Their forecasts range from $36.00 to $53.00. On average, they expect Aclaris Therapeutics' share price to reach $44.50 in the next twelve months. View Analyst Ratings for Aclaris Therapeutics.

What are Wall Street analysts saying about Aclaris Therapeutics stock?

Here are some recent quotes from research analysts about Aclaris Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (2/19/2018)
  • 2. Cantor Fitzgerald analysts commented, "ACRS received approval for Eskata to treat SK. Although approval was expected by the Street, the timing comes ahead of the company’s 12/24 PDUFA date." (12/15/2017)
  • 3. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
  • 4. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)

Who are some of Aclaris Therapeutics' key competitors?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the folowing people:

  • Stephen A. Tullman, Chairman of the Board (Age 51)
  • Neal Walker, President, Chief Executive Officer, Director (Age 47)
  • Frank Ruffo CPA, Chief Financial Officer, Secretary (Age 51)
  • Christopher Powala, Chief Operating Officer (Age 57)
  • Stuart D. Shanler M.D., Chief Scientific Officer (Age 56)
  • Kamil Ali-Jackson J.D., Chief Legal Officer (Age 58)
  • Richard A. Bierly, Independent Director (Age 61)
  • William D. Humphries, Independent Director (Age 50)
  • Anand Mehra M.D., Independent Director (Age 41)
  • Andrew Kenneth William Powell, Independent Director (Age 59)

Who owns Aclaris Therapeutics stock?

Aclaris Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (8.67%), FMR LLC (8.67%), Franklin Resources Inc. (8.42%), BlackRock Inc. (7.12%), Vivo Capital LLC (5.34%) and Driehaus Capital Management LLC (1.70%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew N Schiff, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics.

Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, UBS Asset Management Americas Inc., Goldman Sachs Group Inc., Citadel Advisors LLC, Monashee Investment Management LLC, TIAA CREF Investment Management LLC, Wells Fargo & Company MN and Rock Springs Capital Management LP. View Insider Buying and Selling for Aclaris Therapeutics.

Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?

Aclaris Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., AXA, Driehaus Capital Management LLC, Bank of New York Mellon Corp, Deutsche Bank AG, Schwab Charles Investment Management Inc. and Rice Hall James & Associates LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Andrew N Schiff and Ra Capital Management, Llc. View Insider Buying and Selling for Aclaris Therapeutics.

How do I buy Aclaris Therapeutics stock?

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of Aclaris Therapeutics stock can currently be purchased for approximately $20.19.

How big of a company is Aclaris Therapeutics?

Aclaris Therapeutics has a market capitalization of $622.55 million. The biotechnology company earns $-48,070,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Aclaris Therapeutics employs 31 workers across the globe.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 101 Lindenwood Dr Ste 400, MALVERN, PA 19355-1769, United States. The biotechnology company can be reached via phone at +1-484-3215554 or via email at [email protected]


MarketBeat Community Rating for Aclaris Therapeutics (ACRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aclaris Therapeutics (NASDAQ:ACRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $44.50$41.25$41.25$40.00
Price Target Upside: 127.39% upside67.48% upside71.80% upside49.64% upside

Aclaris Therapeutics (NASDAQ:ACRS) Consensus Price Target History

Price Target History for Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ:ACRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018GuggenheimInitiated CoverageBuy -> Buy$53.00MediumView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00HighView Rating Details
9/8/2017JMP SecuritiesReiterated RatingOutperform$39.00HighView Rating Details
7/31/2017Jefferies GroupReiterated RatingBuy$36.00HighView Rating Details
11/29/2016Leerink SwannInitiated CoverageOutperformN/AView Rating Details
3/16/2016CitigroupLower Price TargetBuy$34.00 -> $29.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Aclaris Therapeutics (NASDAQ:ACRS) Earnings History and Estimates Chart

Earnings by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ ACRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018N/AView Earnings Details
11/7/2017Q3 2017($0.86)($0.63)$2.00 million$0.68 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.68)($0.56)ViewListenView Earnings Details
5/9/2017Q1 2017($0.54)($0.48)ViewListenView Earnings Details
3/15/2017Q4 2016($0.59)($0.49)ViewN/AView Earnings Details
11/3/2016Q3($0.68)($0.50)ViewListenView Earnings Details
8/11/2016Q2($0.61)($0.62)ViewListenView Earnings Details
5/11/2016Q1($0.50)($0.65)ViewListenView Earnings Details
3/23/2016Q4($0.40)($0.28)ViewListenView Earnings Details
11/18/2015Q3 2015($1.46)($5.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aclaris Therapeutics (NASDAQ:ACRS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.59 EPS
Next Year EPS Consensus Estimate: $-4.37 EPS

Dividends

Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aclaris Therapeutics (NASDAQ ACRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 87.06%
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ ACRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017Andrew N SchiffDirectorBuy108,601$23.02$2,499,995.02View SEC Filing  
3/2/2017Ventures Fund Vii L.P. VivoMajor ShareholderSell425,000$30.82$13,098,500.00View SEC Filing  
1/10/2017Anand MehraDirectorSell750,000$28.25$21,187,500.00View SEC Filing  
11/18/2016Ventures Fund Vii L.P. VivoMajor ShareholderSell907,828$23.03$20,907,278.84View SEC Filing  
10/26/2016Kamil Ali-JacksonInsiderSell3,912$21.83$85,398.9679,869View SEC Filing  
9/28/2016Kamil Ali-JacksonInsiderSell1,841$24.66$45,399.0677,798View SEC Filing  
9/16/2016Ra Capital Management, LlcMajor ShareholderSell525,550$24.19$12,713,054.50View SEC Filing  
8/26/2016Kamil Ali-JacksonInsiderSell3,738$20.35$76,068.3020,289View SEC Filing  
2/23/2016Ra Capital Management, LlcMajor ShareholderBuy39,726$17.15$681,300.90View SEC Filing  
1/20/2016Ra Capital Management, LlcMajor ShareholderBuy7,803$19.87$155,045.61View SEC Filing  
1/13/2016Ra Capital Management, LlcMajor ShareholderBuy15,637$19.10$298,666.70View SEC Filing  
10/29/2015Ra Capital Management, LlcMajor ShareholderBuy244,200$14.00$3,418,800.00View SEC Filing  
10/22/2015Ra Capital Management, LlcMajor ShareholderBuy5,410$14.03$75,902.30View SEC Filing  
10/21/2015Ra Capital Management, LlcMajor ShareholderBuy34,999$14.89$521,135.11View SEC Filing  
10/14/2015Ra Capital Management, LlcMajor ShareholderBuy42,813$14.06$601,950.78View SEC Filing  
10/13/2015Albert ChaDirectorBuy454,545$11.00$4,999,995.00View SEC Filing  
10/13/2015Fmr LlcInsiderBuy335,455$11.00$3,690,005.00View SEC Filing  
10/13/2015Sofinnova Venture Partners ViiMajor ShareholderBuy409,090$11.00$4,499,990.00View SEC Filing  
10/8/2015Ra Capital Management, LlcMajor ShareholderBuy2,237,130$10.86$24,295,231.80View SEC Filing  
10/7/2015Vivo Ventures Vii, LlcMajor ShareholderBuy13,352$11.00$146,872.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aclaris Therapeutics (NASDAQ ACRS) News Headlines

Source:
DateHeadline
Zacks Investment Research Upgrades Aclaris Therapeutics (ACRS) to HoldZacks Investment Research Upgrades Aclaris Therapeutics (ACRS) to Hold
www.americanbankingnews.com - February 19 at 4:12 PM
Could These 2 Biotech Stocks Really Double Your Money?Could These 2 Biotech Stocks Really Double Your Money?
finance.yahoo.com - February 15 at 8:25 AM
Aclaris Therapeutics Inc (ACRS) Receives Consensus Recommendation of "Hold" from AnalystsAclaris Therapeutics Inc (ACRS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 13 at 3:48 PM
Aclaris Therapeutics (ACRS) Research Coverage Started at GuggenheimAclaris Therapeutics (ACRS) Research Coverage Started at Guggenheim
www.americanbankingnews.com - February 8 at 8:54 PM
BidaskClub Lowers Aclaris Therapeutics (ACRS) to Strong SellBidaskClub Lowers Aclaris Therapeutics (ACRS) to Strong Sell
www.americanbankingnews.com - February 3 at 9:18 PM
$800,000.00 in Sales Expected for Aclaris Therapeutics Inc (ACRS) This Quarter$800,000.00 in Sales Expected for Aclaris Therapeutics Inc (ACRS) This Quarter
www.americanbankingnews.com - January 24 at 12:56 PM
Aclaris Therapeutics Inc (ACRS) Given Consensus Recommendation of "Hold" by BrokeragesAclaris Therapeutics Inc (ACRS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 19 at 3:40 PM
Malvern firms common warts treatment show promise in mid-stage testingMalvern firm's common warts treatment show promise in mid-stage testing
finance.yahoo.com - January 8 at 3:58 PM
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common WartsAclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
finance.yahoo.com - January 8 at 9:00 AM
Aclaris Therapeutics Inc (ACRS) Expected to Announce Quarterly Sales of $800,000.00Aclaris Therapeutics Inc (ACRS) Expected to Announce Quarterly Sales of $800,000.00
www.americanbankingnews.com - January 7 at 4:30 PM
Aclaris Therapeutics Inc (ACRS) Expected to Announce Earnings of -$0.90 Per ShareAclaris Therapeutics Inc (ACRS) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - January 5 at 3:32 AM
Aclaris Therapeutics (ACRS) Raised to "Hold" at BidaskClubAclaris Therapeutics (ACRS) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - December 29 at 12:36 PM
Aclaris Therapeutics Inc (ACRS) Receives Consensus Rating of "Hold" from BrokeragesAclaris Therapeutics Inc (ACRS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 25 at 1:52 PM
BidaskClub Downgrades Aclaris Therapeutics (ACRS) to SellBidaskClub Downgrades Aclaris Therapeutics (ACRS) to Sell
www.americanbankingnews.com - December 24 at 10:32 AM
FY2018 EPS Estimates for Aclaris Therapeutics Inc Decreased by Jefferies Group (ACRS)FY2018 EPS Estimates for Aclaris Therapeutics Inc Decreased by Jefferies Group (ACRS)
www.americanbankingnews.com - December 20 at 5:28 PM
Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with VitiligoAclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo
finance.yahoo.com - December 19 at 11:09 AM
Blog Exposure - FDA Approves Aclaris Therapeutics ESKATA Topical Solution for Treatment of Common Skin GrowthsBlog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths
finance.yahoo.com - December 18 at 11:39 AM
Aclaris Therapeutics (ACRS) Stock Rating Upgraded by BidaskClubAclaris Therapeutics (ACRS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 17 at 8:40 PM
Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
finance.yahoo.com - December 15 at 11:38 AM
Aclariss drug to treat common skin growth gets FDA nodAclaris's drug to treat common skin growth gets FDA nod
finance.yahoo.com - December 15 at 11:38 AM
Aclaris Therapeutics (ACRS) "Buy" Rating Reaffirmed at Cantor FitzgeraldAclaris Therapeutics' (ACRS) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - December 15 at 9:04 AM
Aclaris Therapeutics, Inc. – Value Analysis (NASDAQ:ACRS) : December 13, 2017Aclaris Therapeutics, Inc. – Value Analysis (NASDAQ:ACRS) : December 13, 2017
finance.yahoo.com - December 13 at 3:59 PM
Aclaris Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACRS-US : December 12, 2017Aclaris Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACRS-US : December 12, 2017
finance.yahoo.com - December 12 at 11:48 AM
 Analysts Anticipate Aclaris Therapeutics Inc (ACRS) Will Announce Quarterly Sales of $800,000.00 Analysts Anticipate Aclaris Therapeutics Inc (ACRS) Will Announce Quarterly Sales of $800,000.00
www.americanbankingnews.com - December 3 at 5:40 AM
Aclaris Therapeutics Inc (ACRS) Receives Average Rating of "Hold" from AnalystsAclaris Therapeutics Inc (ACRS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 30 at 4:04 PM
Financial Analysis: Aclaris Therapeutics (ACRS) versus Its RivalsFinancial Analysis: Aclaris Therapeutics (ACRS) versus Its Rivals
www.americanbankingnews.com - November 18 at 9:14 AM
Zacks: Analysts Expect Aclaris Therapeutics, Inc. (ACRS) Will Announce Quarterly Sales of $800,000.00Zacks: Analysts Expect Aclaris Therapeutics, Inc. (ACRS) Will Announce Quarterly Sales of $800,000.00
www.americanbankingnews.com - November 15 at 6:20 AM
-$0.90 EPS Expected for Aclaris Therapeutics, Inc. (ACRS) This Quarter-$0.90 EPS Expected for Aclaris Therapeutics, Inc. (ACRS) This Quarter
www.americanbankingnews.com - November 13 at 2:37 PM
Brokers Issue Forecasts for Aclaris Therapeutics, Inc.s FY2017 Earnings (ACRS)Brokers Issue Forecasts for Aclaris Therapeutics, Inc.'s FY2017 Earnings (ACRS)
www.americanbankingnews.com - November 10 at 8:48 AM
FY2017 Earnings Forecast for Aclaris Therapeutics, Inc. (ACRS) Issued By Jefferies GroupFY2017 Earnings Forecast for Aclaris Therapeutics, Inc. (ACRS) Issued By Jefferies Group
www.americanbankingnews.com - November 10 at 8:38 AM
Aclaris Therapeutics Mourns the Passing of Board Member Richard A. BierlyAclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly
finance.yahoo.com - November 9 at 4:23 PM
Leerink Swann Comments on Aclaris Therapeutics, Inc.s FY2017 Earnings (ACRS)Leerink Swann Comments on Aclaris Therapeutics, Inc.'s FY2017 Earnings (ACRS)
www.americanbankingnews.com - November 9 at 8:45 AM
Aclaris Therapeutics, Inc. (ACRS) Issues Quarterly  Earnings ResultsAclaris Therapeutics, Inc. (ACRS) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 3:02 PM
Oversold Conditions For Aclaris Therapeutics (ACRS)Oversold Conditions For Aclaris Therapeutics (ACRS)
www.thestreet.com - November 7 at 9:57 PM
Edited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 9:57 PM
Aclaris Therapeutics Reports Third Quarter 2017 Financial ResultsAclaris Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 4:56 PM
Aclaris Therapeutics, Inc. (ACRS) Stock Rating Reaffirmed by Cantor FitzgeraldAclaris Therapeutics, Inc. (ACRS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - November 7 at 12:08 PM
Aclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Buy" by AnalystsAclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 4:02 PM
Aclaris Therapeutics to Attend Upcoming Investor ConferencesAclaris Therapeutics to Attend Upcoming Investor Conferences
finance.yahoo.com - November 3 at 10:18 AM
Aclaris Therapeutics (ACRS) and The Competition Head-To-Head AnalysisAclaris Therapeutics (ACRS) and The Competition Head-To-Head Analysis
www.americanbankingnews.com - October 26 at 7:58 AM
Aclaris Therapeutics, Inc. (ACRS) Set to Announce Earnings on WednesdayAclaris Therapeutics, Inc. (ACRS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:28 AM
Aclaris Therapeutics, Inc. (ACRS) Rating Lowered to Hold at Zacks Investment ResearchAclaris Therapeutics, Inc. (ACRS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:20 PM
Aclaris Therapeutics, Inc. (ACRS) Receives Consensus Rating of "Buy" from AnalystsAclaris Therapeutics, Inc. (ACRS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 11 at 4:44 PM
Aclaris Therapeutics, Inc. (ACRS) Stock Rating Upgraded by Zacks Investment ResearchAclaris Therapeutics, Inc. (ACRS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 10 at 8:56 PM
Aclaris Therapeutics, Inc. (ACRS) PT Set at $50.00 by Cantor FitzgeraldAclaris Therapeutics, Inc. (ACRS) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - October 5 at 9:30 PM
Aclaris Therapeutics (ACRS) and Arrowhead Pharmaceuticals (ARWR) Critical ReviewAclaris Therapeutics (ACRS) and Arrowhead Pharmaceuticals (ARWR) Critical Review
www.americanbankingnews.com - October 2 at 12:22 PM
Cantor Fitzgerald Reaffirms Buy Rating for Aclaris Therapeutics, Inc. (ACRS)Cantor Fitzgerald Reaffirms Buy Rating for Aclaris Therapeutics, Inc. (ACRS)
www.americanbankingnews.com - September 26 at 5:38 PM
Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New YorkAclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York
finance.yahoo.com - September 20 at 3:22 PM
Publication in Dermatologic Surgery Highlights Dose-related EfficacyPublication in Dermatologic Surgery Highlights Dose-related Efficacy
globenewswire.com - September 19 at 8:32 PM
Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic KeratosisAclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
finance.yahoo.com - September 19 at 3:28 PM

SEC Filings

Aclaris Therapeutics (NASDAQ:ACRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aclaris Therapeutics (NASDAQ:ACRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aclaris Therapeutics (NASDAQ ACRS) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.